글로벌 절지동물 매개 바이러스 감염 검사 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

절지동물매개 바이러스 감염 검사 시장 분석

기후 변화, 도시화, 국제 여행 등의 요인으로 인해 이러한 감염의 전 세계적 발생률이 증가함에 따라 정확하고 빠른 검사 솔루션에 대한 수요가 증가했습니다. 이 시장은 분자 검사, 면역 검정, 문화적 방법을 포함한 다양한 진단 도구를 특징으로 합니다 . 최근의 발전에는 보다 민감하고 휴대하기 쉬운 분자 검사의 개발이 포함됩니다. 또한, 공공 보건 기관과 진단 회사 간의 협력은 글로벌 대응 역량을 개선하여 시장 성장을 촉진하는 것을 목표로 합니다.

절지동물 매개 바이러스 감염 검사 시장 규모

글로벌 절지동물 매개 바이러스 감염 검사 시장 규모는 2023년에 11억 4천만 달러로 평가되었으며, 2031년까지 17억 7천만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 5.65%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

절지동물 매개 바이러스 감염 검사 시장 동향

“ 진단 기술의 혁신”

진단 기술의 혁신, 예를 들어 진료 시점 분자 검사 및 면역 검정은 이러한 감염을 더 빠르고 정확하게 탐지하여 시장을 변화시키고 있습니다. 한 가지 주요 추세는 휴대용, 신속한 진단으로의 전환으로, 의료 서비스 제공자가 원격 또는 발병이 발생하기 쉬운 지역의 환자를 신속하게 진단할 수 있게 해줍니다. 이러한 발전은 바이러스 감염의 조기 탐지 및 관리를 개선하여 질병 확산을 줄이고 있습니다. 전 세계 공중 보건 문제가 커짐에 따라 고급 사용자 친화적인 검사 솔루션에 대한 수요가 계속 증가하여 의료 진단 부문에서 중요한 초점 영역이 되었습니다.

보고 범위 및 절지동물 매개 바이러스 감염 검사 시장 세분화

Arthropod-Borne Viral Infections Testing Market Definition

Arthropod-Borne Viral Infections Testing refers to the diagnostic processes used to detect viruses transmitted by arthropods, such as mosquitoes, ticks, and fleas. These viruses, including dengue, Zika, chikungunya, and West Nile, cause diseases that can lead to severe health complications. Testing methods include molecular tests, immunoassays, and culture-based approaches, which help in the timely identification and management of these infections to prevent outbreaks and ensure appropriate treatment.

Arthropod-Borne Viral Infections Testing Market Dynamics

Drivers

• Rising Prevalence of Arthropod-Borne Diseases

The increasing incidence of arthropod-borne diseases such as dengue, Zika, chikungunya, and West Nile virus significantly drives the demand for advanced testing solutions. These viral infections, transmitted primarily through mosquitoes, have seen a notable rise in global cases due to factors such as climate change, urbanization, and increased travel. For instance, dengue cases have surged dramatically in tropical and subtropical regions, prompting urgent healthcare responses. Consequently, there is a pressing need for efficient and reliable diagnostic methods to facilitate early detection and management of these diseases, ultimately enhancing patient outcomes and public health initiatives. This trend underscores the critical need for innovative testing solutions in the market.

• Advancements in Molecular Diagnostic Technologies

Advancements in molecular diagnostic technologies, including polymerase chain reaction (PCR) and next-generation sequencing (NGS), are pivotal in driving growth in the arthropod-borne viral infections testing market. These technologies allow for rapid and precise detection of viral pathogens, significantly enhancing diagnostic accuracy. PCR techniques can identify specific genetic material of viruses within hours, while NGS provides comprehensive genomic data, facilitating the understanding of viral mutations and epidemiology. As healthcare providers increasingly adopt these innovative testing solutions, they can respond more effectively to outbreaks and manage patient care, ultimately propelling the demand for molecular diagnostics in this critical sector of infectious disease testing.

Opportunities

• Telemedicine and Remote Testing Solutions

The rise of telemedicine and remote patient monitoring presents a significant opportunity for the arthropod-borne viral infections testing market, particularly through the development and distribution of at-home testing kits. These kits allow individuals in underserved regions to access diagnostic solutions conveniently, eliminating the barriers posed by distance and healthcare accessibility. As telehealth continues to grow, patients can conduct tests in the comfort of their homes and receive results quickly, facilitating timely medical intervention. This shift enhances patient engagement and reduces the burden on healthcare facilities, driving demand for innovative testing products tailored for remote use in the management of viral infections.

• Vaccine Development and Monitoring

The development of new vaccines for arthropod-borne diseases presents a significant market opportunity for specialized diagnostic solutions focused on efficacy and safety testing. As public health initiatives strive to combat viral infections such as dengue and Zika, the demand for comprehensive testing methods becomes essential to ensure vaccine performance and patient safety. Diagnostic tools that can accurately assess immune responses and identify adverse effects will be crucial in evaluating vaccine candidates during clinical trials and post-marketing surveillance. This need for rigorous testing supports vaccine development and fosters innovation in the diagnostics sector, driving growth and investment in cutting-edge testing technologies.

Restraints/Challenges

• High Cost of Molecular Diagnostic Technologies

The high costs associated with the development and implementation of advanced molecular diagnostic technologies, such as polymerase chain reaction (PCR) and next-generation sequencing (NGS), pose a significant challenge in the arthropod-borne viral infections testing market. These sophisticated technologies require substantial investment in equipment, reagents, and training, making them less accessible for smaller laboratories and healthcare providers, especially in low-resource settings. This financial barrier can lead to disparities in diagnostic capabilities, limiting timely and accurate testing in regions most affected by arthropod-borne diseases. Consequently, this challenge hampers effective disease management and control efforts, highlighting the need for more affordable and accessible testing solutions.

• Inconsistent Disease Surveillance

Variability in disease surveillance systems poses a significant restraint on the arthropod-borne viral infections testing market, as it can lead to incomplete and inconsistent data regarding infection prevalence. In many regions, particularly in low-resource settings, surveillance efforts may be underfunded or poorly organized, resulting in gaps in information about disease outbreaks and transmission patterns. This lack of reliable data can hinder effective public health responses, as decision-makers rely on accurate statistics to allocate resources and implement control measures. Consequently, the uncertainty in disease prevalence diminishes the perceived need for testing, negatively impacting market demand and stifling advancements in diagnostic capabilities.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Arthropod-Borne Viral Infections Testing Market Scope

The market is segmented on the basis of test type and end-user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Test Type

• Molecular Tests
• Cultural Tests
• Immunoassays
• Others

End User

• Hospitals
• Research Centers
• Diagnostic Centers

Arthropod-Borne Viral Infections Testing Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, test type, and end-user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the arthropod-borne viral infections testing market, driven by the swift advancement of diagnostic technologies in the region. The integration of innovative solutions, such as PCR and next-generation sequencing, enhances testing accuracy and efficiency. Furthermore, robust healthcare infrastructure and substantial investment in research contribute to the region's leadership in this market.

The Asia-Pacific region is projected to experience substantial growth in the arthropod-borne viral infections testing market from 2024 to 2031, primarily due to its large population at risk for infections. The high prevalence of arboviruses in this area further exacerbates the demand for effective diagnostic solutions. Additionally, increasing public health awareness and improved healthcare infrastructure are likely to drive this market expansion in the coming years.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Arthropod-Borne Viral Infections Testing Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Arthropod-Borne Viral Infections Testing Market Leaders Operating in the Market Are:

• Thermo Fisher Scientific, Inc. (U.S.)
• BioMérieux (France)
• Hologic, Inc. (U.S.)
• EUROIMMUN Medizinische Labordiagnostika AG (Germany)
• Bio-Rad Laboratories, Inc. (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• InBios International Inc. (U.S.)
• Quest Diagnostics Incorporated(미국)
• CERTEST BIOTEC(스페인)
• Response Biomedical (캐나다)
• Chembio Diagnostics, Inc. (미국)
• 애벗(미국)

절지동물 매개 바이러스 감염 검사 시장의 최신 동향

• 2024년 5월, 글로벌 건강 혁신 기술(GHIT) 기금은 말라리아와 소외된 열대병에 대한 새로운 치료법 개발에 초점을 맞춘 4개 프로젝트를 진행하기 위해 약 16억 4천만 엔(1,080만 달러)의 투자를 발표했습니다. 이 자금 지원 이니셔티브는 서비스가 부족한 지역의 중대한 건강 문제를 해결하려는 조직의 의지를 강조합니다. GHIT는 혁신적인 약물 개발을 지원함으로써 전 세계적으로 영향을 받는 인구의 치료 옵션을 강화하고 건강 결과를 개선하는 것을 목표로 합니다.
• 2023년 5월, Astellas Pharma Inc.는 다양한 감염병과 싸우는 데 사용되는 약물, 진단 도구 및 백신 개발을 지원하는 Global Health Innovative Technology Fund에 대한 지원을 발표했습니다. 이 기여는 종종 충분한 자금과 자원이 부족한 인식이 부족한 열대병에 특히 초점을 맞춥니다. Astellas Pharma는 이 이니셔티브에 투자함으로써 글로벌 건강 결과를 개선하고 감염병 관리의 중요한 격차를 해소하고자 합니다.
• 2022년 7월, Mylab Discovery Solutions는 혁신적인 질병 검사 키트인 'PathoDetect Extended Monsoon Fever Panel'을 출시했습니다. 이 키트는 인상적인 민감도와 특이도를 보여주었습니다. 이 고급 패널은 말라리아, 치쿤구냐, 뎅기열, 지카, 렙토스피라증, 살모넬라증 박테리아 종, 리슈마니아증 기생충을 포함한 여러 감염병을 효과적으로 구별합니다. 이 검사 키트는 여러 병원체를 정확하게 식별할 수 있는 기능을 갖추고 있어 몬순 시즌 동안 진단 기능을 강화하여 영향을 받는 지역의 중대한 건강 문제를 해결합니다.
• 2021년 11월, 스위스의 의료 기술 회사인 아키코(Achico)는 뎅기열을 위한 진단 키트를 개발했다고 발표했습니다. 이 혁신적인 검사 키트는 COVID-19 진단에 효과적인 것으로 입증된 회사의 DNA 앱타머 기술 플랫폼을 활용합니다. 아키코는 이 첨단 기술을 뎅기열 진단에 적용하여 이 중요한 감염병에 대한 검사의 정확성과 효율성을 높이는 것을 목표로 합니다.
• 2021년 11월, 스위스 의료 기술 회사인 아키코(Achico)는 뎅기열 진단 키트를 개발할 계획을 발표했습니다. 이 혁신적인 검사 키트는 이미 COVID-19 진단에 효과가 입증된 회사의 DNA 앱타머 기술 플랫폼을 활용할 것입니다. 이 발전은 뎅기열 진단 역량을 강화하여 신뢰할 수 있는 검사 솔루션에 대한 증가하는 수요를 해결하는 것을 목표로 합니다.

SKU-63602